Research programme: sublingual calcitonin - Albireo PharmaAlternative Names: VIAcal
Latest Information Update: 13 Jan 2017
At a glance
- Originator Biodel
- Class Neuropeptides; Peptide hormones
- Mechanism of Action Bone resorption factor inhibitors; Calcitonin receptor agonists; Osteogenesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 31 Dec 2008 Development discontinued for Osteoporosis before 2009
- 13 Jul 2007 Preclinical trials in Osteoporosis in USA (Sublingual)